Akari Therapeutics, Plc Pre-Tax Income
Akari Therapeutics, Plc (AKTX) reported Pre-Tax Income of -$4.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-13
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$4.81M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$15.31M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$5.21M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$7.49M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$18.30M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$19.79M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$10.01M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.81M 10-Q · filed 2026-08-13 | -$20.12M 10-Q · filed 2026-08-13 | -$25.33M derived: sum of 3 quarters · filed 2026-08-13 | -$32.82M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$15.31M 10-Q · filed 2026-05-19 | -$20.53M derived: sum of 2 quarters · filed 2026-05-19 | -$28.02M derived: sum of 3 quarters · filed 2026-05-19 | -$29.91M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$12.70M derived: sum of 2 quarters · filed 2026-03-30 | -$14.60M derived: sum of 3 quarters · filed 2026-08-13 | -$18.30M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$7.49M 10-Q · filed 2025-11-13 | -$9.38M derived: sum of 2 quarters · filed 2026-08-13 | -$13.09M 10-Q · filed 2025-11-13 | -$16.86M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$1.90M 10-Q · filed 2026-08-13 | -$5.60M 10-Q · filed 2026-08-13 | -$9.37M derived: sum of 3 quarters · filed 2026-08-13 | -$12.27M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$3.71M 10-Q · filed 2026-05-19 | -$7.48M derived: sum of 2 quarters · filed 2026-05-19 | -$10.37M derived: sum of 3 quarters · filed 2026-05-19 | |||
| 2024-12-31 | -$3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$6.67M derived: sum of 2 quarters · filed 2026-03-30 | -$19.79M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$2.90M 10-Q · filed 2025-11-13 | -$16.02M 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | -$10.01M 10-K · filed 2025-04-15 | -$10.01K 10-K · filed 2024-03-29 | ||||
| 2022-12-31 | -$13.16M 8-K · filed 2024-09-06 | -$17.75M 20-F · filed 2023-05-01 | ||||
| 2021-12-31 | -$17.42M 20-F · filed 2023-05-01 | |||||
| 2020-12-31 | -$17.08M 20-F · filed 2023-05-01 | |||||
| 2019-12-31 | -$16.85M 20-F · filed 2022-05-16 | -$17.11M 20-F · filed 2020-03-31 | ||||
| 2018-12-31 | -$20.50M 20-F · filed 2021-04-21 | -$16.47M 20-F · filed 2019-04-23 | ||||
| 2017-12-31 | -$35.40M 20-F · filed 2020-03-31 | |||||
| 2016-12-31 | -$18.14M 20-F · filed 2019-04-23 | |||||
| 2016-03-31 | -$2.99M 10-Q · filed 2016-05-12 | $3.49M derived: sum of 2 quarters · filed 2018-07-18 | -$45.25M derived: sum of 3 quarters · filed 2018-07-18 | -$46.92M derived: sum of 4 quarters · filed 2018-07-18 | ||
| 2015-12-31 | $6.47M derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | -$42.26M derived: sum of 2 quarters · filed 2018-07-18 | -$43.93M derived: sum of 3 quarters · filed 2018-07-18 | -$45.32M 20-F · filed 2018-07-18 | ||
| 2015-09-30 | -$48.74M 10-Q · filed 2015-11-23 | -$50.41M derived: sum of 2 quarters · filed 2015-11-23 | -$51.79M 10-Q · filed 2015-11-23 | -$53.22M derived: sum of 4 quarters · filed 2017-03-31 | ||
| 2015-06-30 | -$1.67M 10-Q · filed 2015-08-12 | -$4.55M 10-Q · filed 2015-08-12 | -$4.48M derived: sum of 3 quarters · filed 2017-03-31 | -$4.70M derived: sum of 4 quarters · filed 2017-03-31 | ||
| 2015-03-31 | -$1.70M 10-Q · filed 2016-05-12 | -$2.88M 10-Q · filed 2015-05-12 | -$2.81M derived: sum of 2 quarters · filed 2017-03-31 | -$3.03M derived: sum of 3 quarters · filed 2017-03-31 | -$5.26M derived: sum of 4 quarters · filed 2017-03-31 | |
| 2014-12-31 | -$1.11M derived: 20-F 12 month − 10-Q 9 month · filed 2017-03-31 | -$1.34M derived: sum of 2 quarters · filed 2017-03-31 | -$3.57M derived: sum of 3 quarters · filed 2017-03-31 | -$1.95M 20-F · filed 2017-03-31 | ||
| 2014-09-30 | -$223.13K 10-Q · filed 2015-11-23 | -$2.45M derived: sum of 2 quarters · filed 2015-11-23 | -$833.74K 10-Q · filed 2015-11-23 | |||
| 2014-06-30 | -$2.23M 10-Q · filed 2015-08-12 | -$3.97M 10-Q · filed 2015-08-12 | ||||
| 2014-03-31 | -$1.74M 10-Q · filed 2015-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |